Archivos De Bronconeumologia最新文献

英文中文

Are Oxygen and Non-Invasive Ventilation Useful "Clean Doping Boosters" for Thoracoabdominal Asynchrony During Exertion in Severe COPD?

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2025.02.012

Michele Vitacca, Mara Paneroni

引用次数: 0

Is Obstructive Sleep Apnea in People Without Obesity a Unique Disease?

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2025.02.014

Atul Malhotra, Ana Lucia Fuentes, Bradley A Edwards

引用次数: 0

Efficacy and Safety of Platelet-Rich Plasma on Bronchopleural Fistula: A Pilot Prospective Cohort Study 富血小板血浆治疗支气管胸膜瘘的有效性和安全性：一项试点前瞻性队列研究

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.06.018

Yongshun Ye , Tingting Xu , Jinxia Lin , Yongna Cai , Zhuquan Su , Liya Lu , Yu Chen , Changgao Zhong , Chunli Tang , Weiquan Xiao , Haojie Liao , Shiyue Li , Xiaobo Chen

Introduction

Bronchopleural fistula (BPF) is associated with high morbidity and mortality rates in patients undergoing pulmonary resections. Surgery, bronchoscopy, and conservative management have their limitations for small fistulas. Platelet-rich plasma (PRP) has regenerative properties, which might be efficient in enhancing tissue recovery and repairing small BPF. This study aimed to investigate efficacy and safety of PRP on BPF.

Methods

This is a pilot prospective cohort study. Patients whose fistulas smaller than 4 mm were enrolled in this study, treated with PRP under bronchoscopy and followed up at 2 weeks and 4–6 weeks after the last PRP treatment. The cure rate, improvement rate and ineffectiveness rate were investigated. The severity of respiratory symptoms was evaluated by modified Medical Research Council dyspnea scale (mMRC) and COPD Assessment Test (CAT). The recurrence of fistula, new infection and mortality rate were examined. Adverse events were documented to explore the safety profile of PRP therapy.

Results

A total of 16 patients (mean age, 50.1 years) met the eligibility criteria. The median time from the first PRP treatment to the closure of the fistula was 12.0 (IQR 6.0, 21.5) days. Our findings indicate an effectiveness rate of 87.6%, with 68.8% of cure and 18.8% of improvement, along with significant improvement of respiratory symptoms evaluated by mMRC (P < 0.001) and CAT (P < 0.001). No recurrent of fistulas, newly developed infection, or death was observed. Adverse events of the procedure were most mild (82.6%) and temporary.

Conclusions

PRP is a potential treatment for small BPF and is well tolerated.

{"title":"Efficacy and Safety of Platelet-Rich Plasma on Bronchopleural Fistula: A Pilot Prospective Cohort Study","authors":"Yongshun Ye , Tingting Xu , Jinxia Lin , Yongna Cai , Zhuquan Su , Liya Lu , Yu Chen , Changgao Zhong , Chunli Tang , Weiquan Xiao , Haojie Liao , Shiyue Li , Xiaobo Chen","doi":"10.1016/j.arbres.2024.06.018","DOIUrl":"10.1016/j.arbres.2024.06.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Bronchopleural fistula (BPF) is associated with high morbidity and mortality rates in patients undergoing pulmonary resections. Surgery, bronchoscopy, and conservative management have their limitations for small fistulas. Platelet-rich plasma (PRP) has regenerative properties, which might be efficient in enhancing tissue recovery and repairing small BPF. This study aimed to investigate efficacy and safety of PRP on BPF.</div></div><div><h3>Methods</h3><div>This is a pilot prospective cohort study. Patients whose fistulas smaller than 4mm were enrolled in this study, treated with PRP under bronchoscopy and followed up at 2 weeks and 4–6 weeks after the last PRP treatment. The cure rate, improvement rate and ineffectiveness rate were investigated. The severity of respiratory symptoms was evaluated by modified Medical Research Council dyspnea scale (mMRC) and COPD Assessment Test (CAT). The recurrence of fistula, new infection and mortality rate were examined. Adverse events were documented to explore the safety profile of PRP therapy.</div></div><div><h3>Results</h3><div>A total of 16 patients (mean age, 50.1 years) met the eligibility criteria. The median time from the first PRP treatment to the closure of the fistula was 12.0 (IQR 6.0, 21.5) days. Our findings indicate an effectiveness rate of 87.6%, with 68.8% of cure and 18.8% of improvement, along with significant improvement of respiratory symptoms evaluated by mMRC (<em>P</em>  <0.001). No recurrent of fistulas, newly developed infection, or death was observed. Adverse events of the procedure were most mild (82.6%) and temporary.</div></div><div><h3>Conclusions</h3><div>PRP is a potential treatment for small BPF and is well tolerated.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 3","pages":"Pages 132-137"},"PeriodicalIF":8.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141692568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucus Plugs as Precursors to Exacerbation and Lung Function Decline in COPD Patients 粘液塞是慢性阻塞性肺病患者病情加重和肺功能下降的前兆

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.07.017

Kwang Nam Jin , Hyo Jin Lee , Heemoon Park , Jung-Kyu Lee , Eun Young Heo , Deog Kyeom Kim , Hyun Woo Lee

Background

Mucus plugs identified through chest computed tomography (CT) scans have emerged as potential prognostic factors in chronic obstructive pulmonary disease (COPD). This 5-year longitudinal study investigated their impact on exacerbations and FEV₁ decline.

Methods

COPD patients with baseline chest CT and spirometric assessments were categorized based on mucus plug presence. Propensity-score matching yielded balanced groups. Exacerbation rates, time to exacerbation events, hazard ratio (HR) for exacerbations, and annual rates of FEV₁ decline were evaluated. Sensitivity analysis was performed with stratification according to mucus plug scores of 0, 1–2, and ≥3.

Results

Among 623 eligible patients, the mucus plug group was 44.3%. Through 1:1 propensity-score matching, each group was comprised of 187 individuals with balanced covariates. The mucus plug group showed higher rates of moderate-to-severe (0.51/year vs. 0.58/year, P = 0.035), severe exacerbations (0.21/year vs. 0.24/year, P = 0.032), and non-eosinophilic exacerbations (0.45/year vs. 0.52/year, P = 0.008). Mucus plugs were associated with increased hazard of moderate-to-severe (adjusted HR = 1.502 [95% CI 1.116–2.020]), severe (adjusted HR = 2.106 [95% CI, 1.429–3.103]), and non-eosinophilic exacerbations (adjusted HR = 1.551 [95% CI, 1.132–2.125]). Annual FEV₁ decline was accelerated in the mucus plug group (β-coefficient = −62 [95% CI, −120 to −5], P = 0.035). Sensitivity analysis showed higher risk of exacerbations and accelerated FEV₁ decline in mucus plug score ≥3 compared to score 0.

Conclusions

Mucus plugs are associated with increased risks of exacerbations, particularly non-eosinophilic, and accelerated FEV₁ declines over 5 years. Our study identified the potential prognostic value of mucus plugs on future exacerbation risks and lung function decline trajectories.

{"title":"Mucus Plugs as Precursors to Exacerbation and Lung Function Decline in COPD Patients","authors":"Kwang Nam Jin , Hyo Jin Lee , Heemoon Park , Jung-Kyu Lee , Eun Young Heo , Deog Kyeom Kim , Hyun Woo Lee","doi":"10.1016/j.arbres.2024.07.017","DOIUrl":"10.1016/j.arbres.2024.07.017","url":null,"abstract":"<div><h3>Background</h3><div>Mucus plugs identified through chest computed tomography (CT) scans have emerged as potential prognostic factors in chronic obstructive pulmonary disease (COPD). This 5-year longitudinal study investigated their impact on exacerbations and FEV<sub>1</sub> decline.</div></div><div><h3>Methods</h3><div>COPD patients with baseline chest CT and spirometric assessments were categorized based on mucus plug presence. Propensity-score matching yielded balanced groups. Exacerbation rates, time to exacerbation events, hazard ratio (HR) for exacerbations, and annual rates of FEV<sub>1</sub> decline were evaluated. Sensitivity analysis was performed with stratification according to mucus plug scores of 0, 1–2, and ≥3.</div></div><div><h3>Results</h3><div>Among 623 eligible patients, the mucus plug group was 44.3%. Through 1:1 propensity-score matching, each group was comprised of 187 individuals with balanced covariates. The mucus plug group showed higher rates of moderate-to-severe (0.51/year vs. 0.58/year, <em>P</em>  =0.032), and non-eosinophilic exacerbations (0.45/year vs. 0.52/year, <em>P</em>          =0.035). Sensitivity analysis showed higher risk of exacerbations and accelerated FEV<sub>1</sub> decline in mucus plug score ≥3 compared to score 0.</div></div><div><h3>Conclusions</h3><div>Mucus plugs are associated with increased risks of exacerbations, particularly non-eosinophilic, and accelerated FEV<sub>1</sub> declines over 5 years. Our study identified the potential prognostic value of mucus plugs on future exacerbation risks and lung function decline trajectories.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 3","pages":"Pages 138-146"},"PeriodicalIF":8.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reproducibility of the Lung Information Needs Questionnaire Via Phone Call Compared With Face-to-face Application in Patients With Chronic Obstructive Pulmonary Disease 慢性阻塞性肺病患者肺部信息需求调查问卷电话调查与面对面调查的可重复性比较

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.10.007

Soraya S. Nohara , Gerson F. Souza , Maria E. Leão , Ana C. Fleury , José R. Jardim

引用次数: 0

A New Method Using Diaphragmatic Ultrasound to Monitor the Work of Breathing During Assisted and Controlled Non-Invasive Ventilation 使用膈肌超声监测辅助和控制性无创通气过程中呼吸功的新方法。

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.10.014

Alba Naya-Prieto , María de los Ángeles Zambrano , Maria del Pilar Carballosa , Itziar Fernández Ormaechea , Carlos López Chang , Pablo Zazu López , Pedro Piñero Gutierrez , María Jesús Rodríguez-Nieto , Germán Peces-Barba Romero , Victoria del Pozo , Sarah Heili-Frades

引用次数: 0

A Rare Case of Cypermethrin Poisoning Presenting as Alveolar Hemorrhage: A Case Report 罕见氯氰菊酯中毒致肺泡出血1例。

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.11.002

Ruhsel Cörüt, Şaban Melih Şimşek

引用次数: 0

Screening Tackles the Big Three: The AGILE Alliance 筛选解决三大问题：敏捷联盟。

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.12.010

David F. Yankelevitz , Matthijs Oudkerk , Claudia I. Henschke

引用次数: 0

Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives. 评估 Elexacaftor/Tezacaftor/Ivacaftor 对 6-11 岁囊性纤维化患儿有氧运动能力的影响：实际观察和临床观点。

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2025.02.010

Margarita Pérez-Ruiz, Mats Te Bos, Patricia Fernández-García, Cristina de Manuel, Ana Morales-Tirado, Alejandro López-Neyra, Marta Ruiz de Valbuena, Margarita Rubio, Verónica Sanz-Santiago

Background: Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies.

Objective: This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6-11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes.

Methods: A multicenter, prospective cohort study was conducted with pediatric CF patients. Participants underwent evaluations 6-8 months before ETI (T1), at the start of ETI (T2), and 6-8 months post-treatment (T3). Primary outcomes included cardiorespiratory fitness assessed via peak oxygen consumption (VO₂peak) during a cardiopulmonary exercise test (CPET), and secondary outcomes encompassed lung function, quality of life, physical activity, and functional mobility.

Results: Of the 28 patients (mean age 9.02±1.59 years), 19 were ETI-naive, and 9 had prior CFTR modulator treatment. Significant improvements were observed in FEV₁ (p<0.001), and several functional mobility tests (30CST, Stair Climb Test, 10MWT). However, VO₂peak showed no significant changes between T1 and T3. Quality of life scores improved notably in emotional, eating, and respiratory domains, and a slight improvement was noted in physical activity levels (p=0.037).

Conclusions: ETI treatment significantly enhances lung function and certain aspects of quality of life and physical fitness in pediatric CF patients. However, it does not significantly alter aerobic capacity (VO₂peak) within the observed period.

{"title":"Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives.","authors":"Margarita Pérez-Ruiz, Mats Te Bos, Patricia Fernández-García, Cristina de Manuel, Ana Morales-Tirado, Alejandro López-Neyra, Marta Ruiz de Valbuena, Margarita Rubio, Verónica Sanz-Santiago","doi":"10.1016/j.arbres.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.arbres.2025.02.010","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies.</p><p><strong>Objective: </strong>This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6-11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes.</p><p><strong>Methods: </strong>A multicenter, prospective cohort study was conducted with pediatric CF patients. Participants underwent evaluations 6-8 months before ETI (T1), at the start of ETI (T2), and 6-8 months post-treatment (T3). Primary outcomes included cardiorespiratory fitness assessed via peak oxygen consumption (VO<sub>2</sub>peak) during a cardiopulmonary exercise test (CPET), and secondary outcomes encompassed lung function, quality of life, physical activity, and functional mobility.</p><p><strong>Results: </strong>Of the 28 patients (mean age 9.02±1.59 years), 19 were ETI-naive, and 9 had prior CFTR modulator treatment. Significant improvements were observed in FEV<sub>1</sub> (p<0.001), and several functional mobility tests (30CST, Stair Climb Test, 10MWT). However, VO<sub>2</sub>peak showed no significant changes between T1 and T3. Quality of life scores improved notably in emotional, eating, and respiratory domains, and a slight improvement was noted in physical activity levels (p=0.037).</p><p><strong>Conclusions: </strong>ETI treatment significantly enhances lung function and certain aspects of quality of life and physical fitness in pediatric CF patients. However, it does not significantly alter aerobic capacity (VO<sub>2</sub>peak) within the observed period.</p>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of Surgical Lung Biopsy in Pleuroparenchymal Fibroelastosis: A Single-center Retrospective Study 胸膜下纤维细胞增生症的手术肺活检结果：单中心回顾性研究

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia

Pub Date : 2025-03-01 DOI: 10.1016/j.arbres.2024.11.009

Haruhiko Shiiya , Tomohiko Nakamura , Hideki Ujiie , Kazuto Ohtaka , Aki Fujiwara-Kuroda , Masato Aragaki , Kazufumi Okada , Tatsuya Kato

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Archivos De Bronconeumologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀